Zobrazeno 1 - 10 of 763 pro vyhledávání: '"Gastoldi S"'
3
Akademický článek
Case report: Timing of eculizumab treatment in catastrophic antiphospholipid syndrome.
Autor: Carrara C; Unit of Nephrology, Azienda Socio-Sanitaria Territoriale Papa Giovanni XXIII, Bergamo, Italy.; Istituto di Ricerche Farmacologiche Mario Negri Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS), Bergamo, Italy., Mataj B; Unit of Nephrology, Azienda Socio-Sanitaria Territoriale Papa Giovanni XXIII, Bergamo, Italy., Gastoldi S; Istituto di Ricerche Farmacologiche Mario Negri Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS), Bergamo, Italy., Ruggenenti P; Unit of Nephrology, Azienda Socio-Sanitaria Territoriale Papa Giovanni XXIII, Bergamo, Italy.; Istituto di Ricerche Farmacologiche Mario Negri Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS), Bergamo, Italy., Sciascia S; University Center of Excellence on Nephrologic, Rheumatologic and Rare Diseases (ERK-Net, ERN-Reconnect and RITA-ERN Member) with Nephrology and Dialysis Unit and Center of Immuno-Rheumatology and Rare Diseases (CMID), Coordinating Center of the Interregional Network for Rare Diseases of Piedmont and Aosta Valley, San Giovanni Bosco Hub Hospital ASL Città di Torino and Department of Clinical and Biological Sciences, Turin, Italy., Roccatello D; University Center of Excellence on Nephrologic, Rheumatologic and Rare Diseases (ERK-Net, ERN-Reconnect and RITA-ERN Member) with Nephrology and Dialysis Unit and Center of Immuno-Rheumatology and Rare Diseases (CMID), Coordinating Center of the Interregional Network for Rare Diseases of Piedmont and Aosta Valley, San Giovanni Bosco Hub Hospital ASL Città di Torino and Department of Clinical and Biological Sciences, Turin, Italy.
Publikováno v: Frontiers in immunology [Front Immunol] 2024 Sep 10; Vol. 15, pp. 1460317. Date of Electronic Publication: 2024 Sep 10 (Print Publication: 2024).
Zobrazit plný text záznamu
4
Akademický článek
Exuberant Endothelial C5b-9 Formation in Recurrent and De Novo Posttransplant Thrombotic Microangiopathy.
Autor: Aiello S; Clinical Research Center for Rare Diseases 'Aldo e Cele Daccò', Istituto di Ricerche Farmacologiche Mario Negri IRCCS, Bergamo, Italy., Gastoldi S; Clinical Research Center for Rare Diseases 'Aldo e Cele Daccò', Istituto di Ricerche Farmacologiche Mario Negri IRCCS, Bergamo, Italy., Bresin E; Clinical Research Center for Rare Diseases 'Aldo e Cele Daccò', Istituto di Ricerche Farmacologiche Mario Negri IRCCS, Bergamo, Italy., Galbusera M; Clinical Research Center for Rare Diseases 'Aldo e Cele Daccò', Istituto di Ricerche Farmacologiche Mario Negri IRCCS, Bergamo, Italy., Mele C; Clinical Research Center for Rare Diseases 'Aldo e Cele Daccò', Istituto di Ricerche Farmacologiche Mario Negri IRCCS, Bergamo, Italy., Daina E; Clinical Research Center for Rare Diseases 'Aldo e Cele Daccò', Istituto di Ricerche Farmacologiche Mario Negri IRCCS, Bergamo, Italy., Santarsiero D; Clinical Research Center for Rare Diseases 'Aldo e Cele Daccò', Istituto di Ricerche Farmacologiche Mario Negri IRCCS, Bergamo, Italy., Comai G; Nephrology Dialysis and Kidney Transplant Unit, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy.; Department of Medical and Surgical Sciences (DIMEC), Alma mater Studiorum - University of Bologna, Italy., La Manna G; Nephrology Dialysis and Kidney Transplant Unit, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy.; Department of Medical and Surgical Sciences (DIMEC), Alma mater Studiorum - University of Bologna, Italy., Martinatto C; Clinical Research Center for Rare Diseases 'Aldo e Cele Daccò', Istituto di Ricerche Farmacologiche Mario Negri IRCCS, Bergamo, Italy., Benigni A; Clinical Research Center for Rare Diseases 'Aldo e Cele Daccò', Istituto di Ricerche Farmacologiche Mario Negri IRCCS, Bergamo, Italy., Remuzzi G; Clinical Research Center for Rare Diseases 'Aldo e Cele Daccò', Istituto di Ricerche Farmacologiche Mario Negri IRCCS, Bergamo, Italy., Noris M; Clinical Research Center for Rare Diseases 'Aldo e Cele Daccò', Istituto di Ricerche Farmacologiche Mario Negri IRCCS, Bergamo, Italy.
Publikováno v: Kidney international reports [Kidney Int Rep] 2024 Aug 22; Vol. 9 (11), pp. 3318-3323. Date of Electronic Publication: 2024 Aug 22 (Print Publication: 2024).
Zobrazit plný text záznamu
5
Akademický článek
Moss-produced human complement factor H with modified glycans has an extended half-life and improved biological activity.
Autor: Tschongov T; Department of Internal Medicine IV (Nephrology), Medical Center, Faculty of Medicine, University of Freiburg, Freiburg, Germany., Konwar S; Department of Internal Medicine IV (Nephrology), Medical Center, Faculty of Medicine, University of Freiburg, Freiburg, Germany., Busch A; Eleva GmbH, Freiburg, Germany., Sievert C; Eleva GmbH, Freiburg, Germany., Hartmann A; Department of Infection Biology, Leibniz Insitute for Natural Product Research and Infection Biology, Jena, Germany., Noris M; Centro di Ricerche Cliniche per le Malattie Rare 'Aldo e Cele Dacco', Istituto di Ricerche Farmacologiche Mario Negri IRCCS, Bergamo, Italy., Gastoldi S; Centro di Ricerche Cliniche per le Malattie Rare 'Aldo e Cele Dacco', Istituto di Ricerche Farmacologiche Mario Negri IRCCS, Bergamo, Italy., Aiello S; Centro di Ricerche Cliniche per le Malattie Rare 'Aldo e Cele Dacco', Istituto di Ricerche Farmacologiche Mario Negri IRCCS, Bergamo, Italy., Schaaf A; Eleva GmbH, Freiburg, Germany., Panse J; Department of Oncology, Hematology, Hemostaseology and Stem Cell Transplantation, University Hospital Rheinisch-Westfälische Technische Hochschule (RWTH) Aachen, Aachen, Germany.; Center for Integrated Oncology (CIO), Aachen, Bonn, Cologne, Düsseldorf (ABCD) Germany Pauwelsstrasse 30, Aachen, Germany., Zipfel PF; Department of Infection Biology, Leibniz Insitute for Natural Product Research and Infection Biology, Jena, Germany.; Institute of Microbiology, Friedrich-Schiller-University, Jena, Germany., Dabrowska-Schlepp P; Eleva GmbH, Freiburg, Germany., Häffner K; Department of Internal Medicine IV (Nephrology), Medical Center, Faculty of Medicine, University of Freiburg, Freiburg, Germany.
Publikováno v: Frontiers in immunology [Front Immunol] 2024 May 10; Vol. 15, pp. 1383123. Date of Electronic Publication: 2024 May 10 (Print Publication: 2024).
Zobrazit plný text záznamu
6
Akademický článek
An ex vivo test to investigate genetic factors conferring susceptibility to atypical haemolytic uremic syndrome.
Autor: Gastoldi S; Clinical Research Center for Rare Diseases Aldo e Cele Daccò and Centro Anna Maria Astori, Science and Technology Park Kilometro Rosso, Istituto di Ricerche Farmacologiche Mario Negri IRCCS, Bergamo, Italy., Aiello S; Clinical Research Center for Rare Diseases Aldo e Cele Daccò and Centro Anna Maria Astori, Science and Technology Park Kilometro Rosso, Istituto di Ricerche Farmacologiche Mario Negri IRCCS, Bergamo, Italy., Galbusera M; Clinical Research Center for Rare Diseases Aldo e Cele Daccò and Centro Anna Maria Astori, Science and Technology Park Kilometro Rosso, Istituto di Ricerche Farmacologiche Mario Negri IRCCS, Bergamo, Italy., Breno M; Clinical Research Center for Rare Diseases Aldo e Cele Daccò and Centro Anna Maria Astori, Science and Technology Park Kilometro Rosso, Istituto di Ricerche Farmacologiche Mario Negri IRCCS, Bergamo, Italy., Alberti M; Clinical Research Center for Rare Diseases Aldo e Cele Daccò and Centro Anna Maria Astori, Science and Technology Park Kilometro Rosso, Istituto di Ricerche Farmacologiche Mario Negri IRCCS, Bergamo, Italy., Bresin E; Clinical Research Center for Rare Diseases Aldo e Cele Daccò and Centro Anna Maria Astori, Science and Technology Park Kilometro Rosso, Istituto di Ricerche Farmacologiche Mario Negri IRCCS, Bergamo, Italy., Mele C; Clinical Research Center for Rare Diseases Aldo e Cele Daccò and Centro Anna Maria Astori, Science and Technology Park Kilometro Rosso, Istituto di Ricerche Farmacologiche Mario Negri IRCCS, Bergamo, Italy., Piras R; Clinical Research Center for Rare Diseases Aldo e Cele Daccò and Centro Anna Maria Astori, Science and Technology Park Kilometro Rosso, Istituto di Ricerche Farmacologiche Mario Negri IRCCS, Bergamo, Italy., Liguori L; Clinical Research Center for Rare Diseases Aldo e Cele Daccò and Centro Anna Maria Astori, Science and Technology Park Kilometro Rosso, Istituto di Ricerche Farmacologiche Mario Negri IRCCS, Bergamo, Italy., Santarsiero D; Clinical Research Center for Rare Diseases Aldo e Cele Daccò and Centro Anna Maria Astori, Science and Technology Park Kilometro Rosso, Istituto di Ricerche Farmacologiche Mario Negri IRCCS, Bergamo, Italy., Benigni A; Clinical Research Center for Rare Diseases Aldo e Cele Daccò and Centro Anna Maria Astori, Science and Technology Park Kilometro Rosso, Istituto di Ricerche Farmacologiche Mario Negri IRCCS, Bergamo, Italy., Remuzzi G; Clinical Research Center for Rare Diseases Aldo e Cele Daccò and Centro Anna Maria Astori, Science and Technology Park Kilometro Rosso, Istituto di Ricerche Farmacologiche Mario Negri IRCCS, Bergamo, Italy., Noris M; Clinical Research Center for Rare Diseases Aldo e Cele Daccò and Centro Anna Maria Astori, Science and Technology Park Kilometro Rosso, Istituto di Ricerche Farmacologiche Mario Negri IRCCS, Bergamo, Italy.
Publikováno v: Frontiers in immunology [Front Immunol] 2023 Feb 09; Vol. 14, pp. 1112257. Date of Electronic Publication: 2023 Feb 09 (Print Publication: 2023).
Zobrazit plný text záznamu
9
Akademický článek
SARS-CoV-2 Spike Protein 1 Activates Microvascular Endothelial Cells and Complement System Leading to Platelet Aggregation.
Autor: Perico L; Istituto di Ricerche Farmacologiche Mario Negri IRCCS, Bergamo, Italy., Morigi M; Istituto di Ricerche Farmacologiche Mario Negri IRCCS, Bergamo, Italy., Galbusera M; Istituto di Ricerche Farmacologiche Mario Negri IRCCS, Bergamo, Italy., Pezzotta A; Istituto di Ricerche Farmacologiche Mario Negri IRCCS, Bergamo, Italy., Gastoldi S; Istituto di Ricerche Farmacologiche Mario Negri IRCCS, Bergamo, Italy., Imberti B; Istituto di Ricerche Farmacologiche Mario Negri IRCCS, Bergamo, Italy., Perna A; Istituto di Ricerche Farmacologiche Mario Negri IRCCS, Bergamo, Italy., Ruggenenti P; Istituto di Ricerche Farmacologiche Mario Negri IRCCS, Bergamo, Italy.; Unit of Nephrology and Dialysis, Azienda Socio Sanitaria Territoriale (ASST) Papa Giovanni XXIII, Bergamo, Italy., Donadelli R; Istituto di Ricerche Farmacologiche Mario Negri IRCCS, Bergamo, Italy., Benigni A; Istituto di Ricerche Farmacologiche Mario Negri IRCCS, Bergamo, Italy., Remuzzi G; Istituto di Ricerche Farmacologiche Mario Negri IRCCS, Bergamo, Italy.
Publikováno v: Frontiers in immunology [Front Immunol] 2022 Mar 07; Vol. 13, pp. 827146. Date of Electronic Publication: 2022 Mar 07 (Print Publication: 2022).
Zobrazit plný text záznamu
10
Report
Case Report: Tackling Complement Hyperactivation With Eculizumab in Atypical Hemolytic Uremic Syndrome Triggered by COVID-19.
Autor: Leone VF; Unit of Nephrology, Azienda Socio-Sanitaria Territoriale Papa Giovanni XXIII, Bergamo, Italy., Imeraj A; Istituto di Ricerche Farmacologiche Mario Negri IRCCS, Milano, Italy., Gastoldi S; Istituto di Ricerche Farmacologiche Mario Negri IRCCS, Milano, Italy., Mele C; Istituto di Ricerche Farmacologiche Mario Negri IRCCS, Milano, Italy., Liguori L; Istituto di Ricerche Farmacologiche Mario Negri IRCCS, Milano, Italy., Condemi C; Unit of Nephrology, Azienda Socio-Sanitaria Territoriale Papa Giovanni XXIII, Bergamo, Italy., Ruggenenti P; Unit of Nephrology, Azienda Socio-Sanitaria Territoriale Papa Giovanni XXIII, Bergamo, Italy., Remuzzi G; Istituto di Ricerche Farmacologiche Mario Negri IRCCS, Milano, Italy., Carrara C; Unit of Nephrology, Azienda Socio-Sanitaria Territoriale Papa Giovanni XXIII, Bergamo, Italy.
Publikováno v: Frontiers in pharmacology [Front Pharmacol] 2022 Feb 28; Vol. 13, pp. 842473. Date of Electronic Publication: 2022 Feb 28 (Print Publication: 2022).
Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání

Omezení vyhledávání
Plný text Recenzováno Digitální knihovna AV ČR
Zdroje